Background Despite strong evidence of benefit, uptake of newer glucose-lowering
medications that reduce cardiovascular risk has been low. We sought to examine global …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Background and aims Type 2 diabetes confers a differential risk of cardiovascular (CV)
disease according to the gender. Whether newly approved anti-diabetic drugs like sodium …

Context Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose
cotransporter-2 inhibitors (SGLT2is) are used off-label in the management of type 1 diabetes …

Aims/hypothesis The safety and efficacy of glucagon-like peptide-1 receptor agonists
(GLP1RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) in major cardiovascular adverse …

Background: Several glucagon-like peptide receptor agonists (GLP-1RA) and sodium-
glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefit in …

Aims/hypothesis Several cardiovascular outcome trials on sodium–glucose cotransporter 2
inhibitors (SGLT2i) have been released recently, including trials enrolling patients with …

The prevalence of heart failure (HF) is increasing in patients with type 2 diabetes (T2D), and
glucose-lowering agents have distinctive effects on the risk of developing HF that requires …

With the emergence of various classes of blood glucose-lowering agents, choosing the
appropriate drug for each patient is emphasized in diabetes management. Among incretin …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-
diabetic drugs that improve glycemic control and many other atherosclerosis-related …